TNFRSF9 and colorectal carcinoma: For this purpose, we used bispecific antibodies engaging CD3-EpCAM or CD137-5T4 (ALG.APV-527) and a colorectal carcinoma cell line HCT116 that coexpresses 5T4 and EpCAM on its surface.